Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD1 | Q96L73 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19783180 | 0.84 | ALDH1A1 (0.42) | NSD1ALDH1A1LMNA | |
| SCHEMBL19782974 | 0.81 | ALDH1A1 (0.53) | NSD1ALDH1A1LMNAGAA | |
| Bromide SCHEMBL28941138 | 0.80 | ALDH1A1 (0.51) | NSD1ALDH1A1LMNAGAA | |
| Bromide SCHEMBL30189638 | 0.80 | ALDH1A1 (0.51) | NSD1ALDH1A1LMNAGAA | |
| SCHEMBL19783461 | 0.79 | NSD1 (0.37) | NSD1ALDH1A1LMNAMGAMGAA | |
| SCHEMBL19783063 | 0.79 | NSD1 (0.37) | NSD1ALDH1A1LMNA | |
| SCHEMBL19783064 | 0.76 | ALDH1A1 (0.36) | ALDH1A1GAA | |
| SCHEMBL19783123 | 0.73 | S1PR4 (0.32) | — | |
| SCHEMBL19783141 | 0.71 | — | — | |
| SCHEMBL19783084 | 0.71 | PKM (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | NSD1 3382/4885HSD17B1 2072/4885HSD17B2 2015/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | NSD1 3520/4885HSD17B1 2402/4885HSD17B2 2273/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | NSD1 3382/4885HSD17B1 2072/4885HSD17B2 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.